ESSA Pharma (EPIX) Stock Forecast, Price & News

ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company has collaboration agreements with Caris Life Sciences, Inc.; Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.

Wall Street Analyst Weigh In

Separately, Piper Sandler lowered their price target on shares of ESSA Pharma from $50.00 to $20.00 in a report on Thursday, May 12th.

ESSA Pharma Price Performance

EPIX traded down $0.02 during trading hours on Friday, reaching $3.00. 213,388 shares of the stock traded hands, compared to its average volume of 899,704. ESSA Pharma has a fifty-two week low of $2.41 and a fifty-two week high of $21.85. The company has a market cap of $132.06 million, a price-to-earnings ratio of -3.49 and a beta of 1.59. The firm's fifty day simple moving average is $3.64 and its two-hundred day simple moving average is $6.03.

ESSA Pharma (NASDAQ:EPIX - Get Rating) (TSE:EPI) last posted its quarterly earnings data on Tuesday, May 10th. The company reported ($0.25) EPS for the quarter, meeting analysts' consensus estimates of ($0.25). On average, research analysts predict that ESSA Pharma will post -1.02 earnings per share for the current year.

Insider Transactions at ESSA Pharma

In other ESSA Pharma news, major shareholder Growth N. V. Biotech purchased 300,000 shares of ESSA Pharma stock in a transaction dated Monday, July 18th. The shares were bought at an average cost of $3.16 per share, for a total transaction of $948,000.00. Following the transaction, the insider now owns 5,879,583 shares in the company, valued at approximately $18,579,482.28. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In other news, major shareholder Growth N. V. Biotech acquired 347,204 shares of the company's stock in a transaction that occurred on Thursday, July 14th. The shares were acquired at an average price of $2.79 per share, with a total value of $968,699.16. Following the acquisition, the insider now directly owns 5,337,918 shares in the company, valued at $14,892,791.22. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, major shareholder Growth N. V. Biotech acquired 300,000 shares of the company's stock in a transaction that occurred on Monday, July 18th. The stock was purchased at an average cost of $3.16 per share, for a total transaction of $948,000.00. Following the acquisition, the insider now owns 5,879,583 shares in the company, valued at $18,579,482.28. The disclosure for this purchase can be found here. In the last three months, insiders have acquired 652,091 shares of company stock worth $1,931,165. 9.90% of the stock is currently owned by insiders.